Glover v. Cohen — Supreme Court Petition Denied in Facial Cleanser Patent Dispute
Morris S. Glover petitioned the U.S. Supreme Court against Daniel E. Cohen over two patents — a design patent and a utility patent — covering a facial cleanser product. The petition was denied within 362 days, ending Glover’s bid for Supreme Court review without reaching the merits.
Supreme Court closes the door on facial cleanser patent petition
Filed on February 23, 2023, Case No. 23-607 brought Morris S. Glover before the U.S. Supreme Court in Washington, D.C., seeking judicial review of a prior infringement action against Daniel E. Cohen. The dispute centres on two patents: USD351924S, a design patent for a facial cleanser, and US5466456A, a utility patent covering related technology. The case reached the nation’s highest court as a petition for certiorari, the standard vehicle for seeking Supreme Court review of lower-court decisions.
On February 20, 2024 — 362 days after filing — the Supreme Court denied the petition, recorded as ‘Petition Dismissed’ in the docket. A cert denial is not a ruling on the merits; it signals that fewer than four justices voted to grant review. For Cohen, the denial leaves any favourable lower-court outcome intact. For Glover, all avenues for federal appellate relief on these patents are now exhausted at the Supreme Court level.
The timeline of just under one year is broadly consistent with how the Supreme Court processes cert petitions, suggesting no unusual procedural complications. The denial leaves the underlying merits — including which party prevailed below and on what grounds — not adjudicated by the Supreme Court. The public record does not disclose settlement terms, licensing arrangements, or the specific lower-court decision that prompted the petition, making it difficult to assess the full commercial context of the dispute.
Filing to dismissal in 362 days
362 days from filing to Supreme Court denial — consistent with typical cert petition timelines
What a Supreme Court cert denial means for both parties
Cert denial is not a ruling on the merits
When the Supreme Court denies a petition for certiorari, it does not affirm or reverse the lower court’s decision. It simply means the Court declined to take the case — typically because fewer than four justices voted to grant review. The denial says nothing about whether Glover’s infringement claims were valid or meritorious. Any lower-court judgment in Cohen’s favour remains standing, but without Supreme Court endorsement of its reasoning.
Petition denied — merits untouchedNo binding precedent created by this denial
A cert denial creates no binding legal precedent. Attorneys and courts cannot cite it as authority on facial cleanser patent law, design patent scope, or any underlying claim construction issues. For practitioners monitoring this technology space, the denial closes this particular dispute without clarifying the broader legal questions it may have raised. Future litigants in the facial cleanser patent space must look to lower-court decisions and any published opinions from the courts below.
Zero precedential effectGlover’s Supreme Court avenue is now exhausted
With the petition denied, Glover has exhausted federal appellate review at the Supreme Court level for this case. Unless new facts emerge — such as newly discovered evidence or a separate cause of action — the denial effectively ends this litigation chapter. Glover could theoretically pursue separate proceedings or re-examine patent enforcement in other jurisdictions, but the Supreme Court denial forecloses any further review of the lower court’s decision on these specific facts.
No further federal appealCohen retains the benefit of the lower court outcome
For Cohen, the cert denial is effectively a win in the sense that the lower court’s decision — which presumably favoured him, prompting Glover to seek Supreme Court review — now stands as final. Cohen faces no obligation to relitigate these patent claims at the Supreme Court level. The denial also signals that the Court saw no compelling reason to disturb the legal reasoning applied in the courts below, which may strengthen Cohen’s position in any related commercial or licensing contexts.
Lower court outcome preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Morris S. Glover | Company | Patent holder asserting facial cleanser design and utility rights — holder of USD351924S and US5466456ASearch in Eureka ↗ |
| Defendant | Daniel E. Cohen | Company | Daniel E. Cohen — respondent in Supreme Court petition arising from facial cleanser patent infringement actionSearch in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | U.S. Supreme Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The docket records a terse ‘Petition DENIED’ — standard Supreme Court language for a certiorari denial. This phrasing confirms the Court exercised its discretionary jurisdiction to decline review, leaving the lower-court outcome undisturbed. It does not indicate agreement or disagreement with the legal arguments advanced by either party. For Cohen, the denial is the functional terminus of the dispute. For Glover, it closes the highest available federal appellate forum on these patent claims.
USD351924S & US5466456A — Facial Cleanser Design and Utility Patents
USD351924S is a U.S. design patent protecting the ornamental appearance of a facial cleanser product, filed under application number US07/798799. US5466456A is a utility patent — application number US08/090565 — covering functional aspects of a facial cleanser, consistent with formulation or delivery mechanism protection. Together, they represent a dual-layer IP position: aesthetic protection via the design patent and functional protection via the utility grant. Both originate from application filings predating the litigation by a significant margin, suggesting established IP assets rather than newly filed patents.
In the personal care sector, holding both design and utility rights over the same product category creates meaningful defensive depth. Competitors attempting to design around one patent face exposure from the other. The fact that these patents generated litigation reaching the U.S. Supreme Court — even as a cert petition — suggests they cover commercially relevant product features. Any company developing, manufacturing, or distributing facial cleansers with similar ornamental or functional characteristics should treat these patents as active IP risk factors until their expiry status is independently confirmed.
Should your team run an FTO against USD351924S and US5466456A?
If your organisation develops, sources, or markets facial cleansers — whether as a brand, contract manufacturer, or private label supplier — both USD351924S and US5466456A represent patents that warrant review in any freedom-to-operate analysis. The dual assertion of design and utility patents in this dispute signals that the IP owner pursued broad product coverage. R&D teams working on facial cleanser formulations, dispensing mechanisms, or product packaging should specifically assess whether their designs intersect with the claims and ornamental scope of these two patents.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US5466456A and the design scope of USD351924S against your product specifications, flagging overlap risk before market entry. Eureka’s claim monitoring tools can also alert your team to any continuation filings, reissue applications, or related patents in the same family — critical for a product category where enforcement has demonstrably reached Supreme Court level. Start with a targeted FTO query for both patent numbers to identify the full risk perimeter.
Run a freedom-to-operate analysis on USD0351924S to assess your product’s exposure
Run FTO in Eureka →Similar facial cleanser and personal care patent infringement cases
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the cosmetics and personal care IP landscape
A Supreme Court petition over facial cleanser patents reveals how aggressively design and utility rights are being enforced in personal care product categories.
Design patents in personal care are worth fighting to the highest court
This case reached the U.S. Supreme Court, suggesting Glover viewed the design and utility rights covering this facial cleanser as commercially significant enough to exhaust every appellate avenue. For companies in personal care and cosmetics, it underscores that design patents like USD351924S can attract high-stakes enforcement activity well beyond the district court level.
Cert denials leave lower-court IP reasoning intact — monitor those opinions
Because the Supreme Court did not address the merits, the legal reasoning from the lower courts in this dispute remains the operative authority. IP teams competing in the facial cleanser space should obtain and review any published lower-court opinions from this case chain — those opinions shape the claim scope landscape for USD351924S and US5466456A going forward.
Morris v Daniel — key questions answered
The U.S. Supreme Court denied Morris S. Glover’s petition for certiorari in Case No. 23-607 on February 20, 2024. Glover had sought Supreme Court review of a lower-court decision in a patent infringement action involving facial cleanser patents USD351924S and US5466456A against Daniel E. Cohen. The denial leaves the lower court’s outcome intact without the Supreme Court addressing the merits.
Two patents were asserted: USD351924S, a U.S. design patent protecting the ornamental design of a facial cleanser (application US07/798799), and US5466456A, a utility patent covering functional aspects of a facial cleanser (application US08/090565). The dual assertion of design and utility patents suggests a layered enforcement strategy covering both aesthetic and functional product attributes.
A cert denial is not a ruling on the merits. It means the Supreme Court declined to review the lower court’s decision — typically because fewer than four justices voted to grant review. For Glover, it exhausts federal appellate options at the Supreme Court level. For Cohen, any favourable lower-court ruling remains standing. No binding legal precedent is created by the denial.
The petition was filed on February 23, 2023 and denied on February 20, 2024 — a duration of 362 days. This timeline is broadly consistent with typical certiorari petition processing timelines at the U.S. Supreme Court, suggesting no unusual procedural delays or extensions in this matter.
The cert denial does not extinguish the underlying patents USD351924S and US5466456A. Both patents remain potentially enforceable until their expiry dates, which should be independently verified. Facial cleanser manufacturers, formulators, and private label suppliers should conduct freedom-to-operate analysis against both patents before market entry, as the litigation history demonstrates a patent holder willing to pursue enforcement to the Supreme Court level.
PatSnap Eureka searches patents and litigation data to answer instantly.